Remove Clinic Remove Diagnostic Remove Disease Remove Events
article thumbnail

Interstitial lung abnormalities linked to respiratory disease risk

AuntMinnie

CT imaging shows that severe acute respiratory disease events can be caused by quantitative interstitial abnormalities (QIA) -- that is, small irregularities that don't necessarily meet diagnostic criteria for advanced pulmonary diseases but show up on CT exams over time, a study published April 30 in Radiology has reported.

Disease 111
article thumbnail

Lung Abnormality Progression Linked to Acute Respiratory Disease in Smokers

Imaging Technology

milla1cf Fri, 05/24/2024 - 07:00 May 24, 2024 — Smokers who have small abnormalities on their CT scans that grow over time have a greater likelihood of experiencing acute respiratory disease events, according to a new study published today in Radiology , a journal of the Radiological Society of North America ( RSNA ).

Disease 68
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Dartmouth event bats around promise, shortcomings of AI in healthcare

AuntMinnie

Langlotz's laboratory investigates the use of deep neural networks and other machine-learning technologies to detect disease and eliminate diagnostic errors through analysis of medical images and clinical notes. Photo courtesy of Dartmouth.

article thumbnail

CAC score may predict heart attack, stroke risk

AuntMinnie

Coronary artery calcium (CAC) scoring with CT could determine whether patients with heart disease symptoms are at low risk of heart attacks or strokes, according to a study published March 5 in Radiology. years for any major adverse cardiovascular events. risk rate of major adverse cardiovascular events.

Disease 108
article thumbnail

Blue Earth Diagnostics Highlights Presentations on POSLUMA (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting

Imaging Technology

PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Chief Executive Officer of Blue Earth Diagnostics. from October 1 to 4, 2023. Gauden , D.Phil., Kuo, MD, Ph.D.,

article thumbnail

ConcertAI's TeraRecon, Integrates Clinical and Generative AI, Supporting Clinical Research and Advancing Clinical Care Solutions at RSNA23

Imaging Technology

milla1cf Mon, 11/27/2023 - 14:13 November 27, 2023 — ConcertAI 's TeraRecon , the advanced visualization and clinical AI leader, recently unveiled first-in-category capabilities in advanced visualization, AI, and expansions to its AI partner ecosystem to enhance research capabilities and support complex clinical study workflows.

Clinic 52
article thumbnail

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Imaging Technology

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Chief Executive Officer of Blue Earth Diagnostics. Gauden , D.Phil., The adverse reactions reported in ≥0.4%